United States Biotechnology & Medical Research

Alder Biopharmaceuticals Inc (ALDR)

Track

Track

Ticker: ALDR Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
No insider activity signals detected

Insider trades have not triggered unusual activity signals for this company.

Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
H LUNDBECK A S Large shareholder
Transaction date
Purchase
Price
183.45
Quantity 98,082
Value US$893,752
2.5
Smith Jeffrey T L Managing Director
Transaction date
Planned sale
Price
98.42
Quantity 2,591 -10.2%
Value US$2,476,179
Benedict Larry EVP and PAO
Transaction date
Planned sale
Price
25.03
Quantity 65,445 -40.1%
Value US$4,476,064
Lavelle Erin Chief Operating Officer
Transaction date
Planned sale
Price
13.67
Quantity 1,434 -24.5%
Value US$19,599
Hassler Randal EVP, Pharmaceutical Ops.
Transaction date
Planned sale
Price
13.85
Quantity 1,738 -24.2%
Value US$24,067
Bucher James B EVP & General Counsel
Transaction date
Planned sale
Price
13.85
Quantity 1,897 -16.2%
Value US$26,281
Smith Jeffrey T L Managing Director Officer
Transaction date
Planned sale
Price
13.84
Quantity 5,044 -85.9%
Value US$69,826
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
13.78
Quantity 1,319 -0.5%
Value US$18,170
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
13.40
Quantity 23,683 -8.8%
Value US$317,419
Smith Jeffrey T L Managing Director Officer
Transaction date
Planned sale
Price
13.42
Quantity 5,040 -85.8%
Value US$67,637
Smith Jeffrey T L Managing Director Officer
Transaction date
Planned sale
Price
15.97
Quantity 2,000 -70.6%
Value US$31,944
Smith Jeffrey T L Managing Director Officer
Transaction date
Planned sale
Price
15.26
Quantity 3,040 -51.8%
Value US$46,385
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
15.97
Quantity 6,554 -2.6%
Value US$104,692
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
15.25
Quantity 18,445 -6.9%
Value US$281,314
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
17.99
Quantity 24,999 -9.3%
Value US$449,680
Smith Jeffrey T L Managing Director Officer
Transaction date
Planned sale
Price
18.00
Quantity 5,040 -85.8%
Value US$90,699
Smith Jeffrey T L Managing Director Officer
Transaction date
Planned sale
Price
19.76
Quantity 980 -54.1%
Value US$19,369
Smith Jeffrey T L Managing Director Officer
Transaction date
Planned sale
Price
19.49
Quantity 4,060 -69.2%
Value US$79,120
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
19.55
Quantity 24,999 -9.3%
Value US$488,768
Smith Jeffrey T L Managing Director Officer
Transaction date
Planned sale
Price
15.49
Quantity 12,161 -93.6%
Value US$188,364
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
15.48
Quantity 24,999 -9.3%
Value US$387,002
Litton Mark James Chief Business Officer Officer
Transaction date
Planned sale
Price
18.24
Quantity 4,474 -4.2%
Value US$81,587
Litton Mark James Chief Business Officer Officer
Transaction date
Planned sale
Price
17.74
Quantity 18,253 -14.6%
Value US$323,825
Smith Jeffrey T L Managing Director Officer
Transaction date
Planned sale
Price
18.29
Quantity 1,100 -57.0%
Value US$20,115
Smith Jeffrey T L Managing Director Officer
Transaction date
Planned sale
Price
17.81
Quantity 11,061 -85.1%
Value US$197,012
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
18.25
Quantity 4,799 -1.9%
Value US$87,562
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
17.76
Quantity 20,200 -7.5%
Value US$358,794
Smith Jeffrey T L Managing Director Officer
Transaction date
Planned sale
Price
15.03
Quantity 12,161 -93.6%
Value US$182,758
Litton Mark James Chief Business Officer
Transaction date
Planned sale
Price
10.80
Quantity 16,519 -14.2%
Value US$178,486
Litton Mark James Chief Business Officer
Transaction date
Planned sale
Price
12.33
Quantity 16,520 -14.2%
Value US$203,703
YARNO WENDY L Non-Executive Director
Transaction date
Purchase
Price
10.00
Quantity 5,000 +inf%
Value US$50,000
DOW STEPHEN M Non-Executive Director
Transaction date
Purchase
Price
10.00
Quantity 25,000 +8.9%
Value US$250,000
Smith Jeffrey T L Sr. VP Translational Medicine
Transaction date
Planned sale
Price
20.00
Quantity 585 -41.3%
Value US$11,700
Schatzman Randall C President and CEO Executive Director
Transaction date
Planned sale
Price
25.03
Quantity 30,000 -20.7%
Value US$750,756
Litton Mark James Chief Business Officer
Transaction date
Planned sale
Price
23.10
Quantity 1,498 -1.5%
Value US$34,599
Litton Mark James Chief Business Officer
Transaction date
Planned sale
Price
23.00
Quantity 500 -0.5%
Value US$11,500
Litton Mark James Chief Business Officer
Transaction date
Planned sale
Price
23.02
Quantity 6,800 -6.4%
Value US$156,520
Litton Mark James Chief Business Officer
Transaction date
Planned sale
Price
23.00
Quantity 2,216 -2.2%
Value US$50,972
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
23.62
Quantity 500 -0.2%
Value US$11,810
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
22.64
Quantity 3,136 -1.3%
Value US$71,002
Smith Jeffrey T L Sr. VP Translational Medicine Officer
Transaction date
Planned sale
Price
23.62
Quantity 500 -37.6%
Value US$11,810
Smith Jeffrey T L Sr. VP Translational Medicine Officer
Transaction date
Planned sale
Price
22.61
Quantity 2,500 -65.3%
Value US$56,518
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
30.18
Quantity 10,000 -4.0%
Value US$301,839
Schatzman Randall C President and CEO Executive Director
Transaction date
Planned sale
Price
25.16
Quantity 10,000 -8.0%
Value US$251,605
Smith Jeffrey T L Sr. VP Translational Medicine Officer
Transaction date
Planned sale
Price
24.88
Quantity 400 -100.0%
Value US$9,950
Smith Jeffrey T L Sr. VP Translational Medicine Officer
Transaction date
Planned sale
Price
24.26
Quantity 2,600 -86.7%
Value US$63,082
Litton Mark James Chief Business Officer Officer
Transaction date
Planned sale
Price
27.50
Quantity 2,000 -7.1%
Value US$55,000
Litton Mark James Chief Business Officer Officer
Transaction date
Planned sale
Price
27.50
Quantity 2,000 -7.1%
Value US$55,005
Litton Mark James Chief Business Officer Officer
Transaction date
Planned sale
Price
27.50
Quantity 2,000 -7.1%
Value US$54,993
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
31.51
Quantity 6,249 -2.5%
Value US$196,888
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
31.00
Quantity 3,751 -1.5%
Value US$116,263
Smith Jeffrey T L Sr. VP Translational Medicine Officer
Transaction date
Planned sale
Price
31.62
Quantity 702 -100.0%
Value US$22,199
Smith Jeffrey T L Sr. VP Translational Medicine Officer
Transaction date
Planned sale
Price
30.99
Quantity 2,298 -76.6%
Value US$71,216
Schatzman Randall C President and CEO Executive Director
Transaction date
Planned sale
Price
31.55
Quantity 2,700 -2.3%
Value US$85,189
Schatzman Randall C President and CEO Executive Director
Transaction date
Planned sale
Price
30.95
Quantity 5,481 -4.5%
Value US$169,622
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
32.49
Quantity 10,000 -4.0%
Value US$324,949
Schatzman Randall C President and CEO Executive Director
Transaction date
Planned sale
Price
32.48
Quantity 10,000 -8.0%
Value US$324,820
Smith Jeffrey T L Sr. VP Translational Medicine Officer
Transaction date
Planned sale
Price
33.10
Quantity 100 -100.0%
Value US$3,310
Smith Jeffrey T L Sr. VP Translational Medicine Officer
Transaction date
Planned sale
Price
32.47
Quantity 2,900 -96.7%
Value US$94,173
Smith Jeffrey T L Sr. VP Translational Medicine Officer
Transaction date
Sale
Price
31.17
Quantity 3,000 -100.0%
Value US$93,512
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
32.54
Quantity 32 -0.0%
Value US$1,041
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
30.88
Quantity 6,394 -2.5%
Value US$197,423
Schatzman Randall C President and CEO Executive Director
Transaction date
Planned sale
Price
32.69
Quantity 16 -0.0%
Value US$523
Schatzman Randall C President and CEO Executive Director
Transaction date
Planned sale
Price
31.68
Quantity 4,816 -4.0%
Value US$152,570
Schatzman Randall C President and CEO Executive Director
Transaction date
Planned sale
Price
30.65
Quantity 5,168 -4.1%
Value US$158,420
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
30.15
Quantity 9,187 -3.7%
Value US$277,023
Latham John A Chief Scientific Officer Officer
Transaction date
Planned sale
Price
30.00
Quantity 813 -0.3%
Value US$24,392
Schatzman Randall C President and CEO Executive Director
Transaction date
Planned sale
Price
28.08
Quantity 10,000 -8.0%
Value US$280,805
Litton Mark James Chief Business Officer Officer
Transaction date
Planned sale
Price
29.64
Quantity 200 -0.7%
Value US$5,928
Litton Mark James Chief Business Officer Officer
Transaction date
Planned sale
Price
28.90
Quantity 1,800 -6.0%
Value US$52,012
Litton Mark James Chief Business Officer Officer
Transaction date
Planned sale
Price
29.60
Quantity 100 -0.4%
Value US$2,960
Litton Mark James Chief Business Officer Officer
Transaction date
Planned sale
Price
28.89
Quantity 1,900 -6.3%
Value US$54,900
Litton Mark James Chief Business Officer Officer
Transaction date
Planned sale
Price
29.60
Quantity 100 -0.4%
Value US$2,960
Litton Mark James Chief Business Officer Officer
Transaction date
Planned sale
Price
28.90
Quantity 1,900 -6.3%
Value US$54,903
Smith Jeffrey T L Sr. VP Translational Medicine Officer
Transaction date
Sale
Price
31.83
Quantity 1,000 -100.0%
Value US$31,827
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2019-10-24 2019-10-22 B Purchase
H LUNDBECK A S
Large shareholder
98,082
183.45
US$893,752 		98,082 183.45 US$893,752
2019-09-18 2019-09-16 PlS Planned sale
2.5
Smith Jeffrey T L

Managing Director
2,591 -10.2%
98.42
US$2,476,179 		2,591 -10.2% 98.42 US$2,476,179
2019-04-25 2019-04-25 PlS Planned sale
Benedict Larry

EVP and PAO
65,445 -40.1%
25.03
US$4,476,064 		65,445 -40.1% 25.03 US$4,476,064
2019-04-25 2019-04-25 PlS Planned sale
Lavelle Erin

Chief Operating Officer
1,434 -24.5%
13.67
US$19,599 		1,434 -24.5% 13.67 US$19,599
2019-04-25 2019-04-25 PlS Planned sale
Hassler Randal

EVP, Pharmaceutical Ops.
1,738 -24.2%
13.85
US$24,067 		1,738 -24.2% 13.85 US$24,067
2019-04-25 2019-04-25 PlS Planned sale
Bucher James B

EVP & General Counsel
1,897 -16.2%
13.85
US$26,281 		1,897 -16.2% 13.85 US$26,281
2018-12-04 2018-12-03 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
5,044 -85.9%
13.84
US$69,826 		5,044 -85.9% 13.84 US$69,826
2018-11-05 2018-11-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
1,319 -0.5%
13.78
US$18,170 		1,319 -0.5% 13.78 US$18,170
2018-11-05 2018-11-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
23,683 -8.8%
13.40
US$317,419 		23,683 -8.8% 13.40 US$317,419
2018-11-05 2018-11-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
5,040 -85.8%
13.42
US$67,637 		5,040 -85.8% 13.42 US$67,637
2018-10-03 2018-10-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
2,000 -70.6%
15.97
US$31,944 		2,000 -70.6% 15.97 US$31,944
2018-10-03 2018-10-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
3,040 -51.8%
15.26
US$46,385 		3,040 -51.8% 15.26 US$46,385
2018-10-03 2018-10-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
6,554 -2.6%
15.97
US$104,692 		6,554 -2.6% 15.97 US$104,692
2018-10-03 2018-10-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
18,445 -6.9%
15.25
US$281,314 		18,445 -6.9% 15.25 US$281,314
2018-09-06 2018-09-04 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
24,999 -9.3%
17.99
US$449,680 		24,999 -9.3% 17.99 US$449,680
2018-09-06 2018-09-04 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
5,040 -85.8%
18.00
US$90,699 		5,040 -85.8% 18.00 US$90,699
2018-08-02 2018-08-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
980 -54.1%
19.76
US$19,369 		980 -54.1% 19.76 US$19,369
2018-08-02 2018-08-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
4,060 -69.2%
19.49
US$79,120 		4,060 -69.2% 19.49 US$79,120
2018-08-02 2018-08-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
24,999 -9.3%
19.55
US$488,768 		24,999 -9.3% 19.55 US$488,768
2018-07-03 2018-07-02 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
12,161 -93.6%
15.49
US$188,364 		12,161 -93.6% 15.49 US$188,364
2018-07-03 2018-07-02 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
24,999 -9.3%
15.48
US$387,002 		24,999 -9.3% 15.48 US$387,002
2018-06-05 2018-06-01 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
4,474 -4.2%
18.24
US$81,587 		4,474 -4.2% 18.24 US$81,587
2018-06-05 2018-06-01 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
18,253 -14.6%
17.74
US$323,825 		18,253 -14.6% 17.74 US$323,825
2018-06-05 2018-06-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
1,100 -57.0%
18.29
US$20,115 		1,100 -57.0% 18.29 US$20,115
2018-06-05 2018-06-01 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
11,061 -85.1%
17.81
US$197,012 		11,061 -85.1% 17.81 US$197,012
2018-06-05 2018-06-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
4,799 -1.9%
18.25
US$87,562 		4,799 -1.9% 18.25 US$87,562
2018-06-05 2018-06-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
20,200 -7.5%
17.76
US$358,794 		20,200 -7.5% 17.76 US$358,794
2018-05-18 2018-05-16 PlS Planned sale Smith Jeffrey T L

Managing Director

Officer
12,161 -93.6%
15.03
US$182,758 		12,161 -93.6% 15.03 US$182,758
2017-11-15 2017-11-13 PlS Planned sale Litton Mark James

Chief Business Officer
16,519 -14.2%
10.80
US$178,486 		16,519 -14.2% 10.80 US$178,486
2017-10-18 2017-10-16 PlS Planned sale Litton Mark James

Chief Business Officer
16,520 -14.2%
12.33
US$203,703 		16,520 -14.2% 12.33 US$203,703
2017-07-18 2017-07-18 B Purchase YARNO WENDY L Non-Executive Director
5,000 +inf%
10.00
US$50,000 		5,000 +inf% 10.00 US$50,000
2017-07-18 2017-07-18 B Purchase DOW STEPHEN M Non-Executive Director
25,000 +8.9%
10.00
US$250,000 		25,000 +8.9% 10.00 US$250,000
2017-06-22 2017-06-20 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine
585 -41.3%
20.00
US$11,700 		585 -41.3% 20.00 US$11,700
2017-02-13 2017-02-09 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
30,000 -20.7%
25.03
US$750,756 		30,000 -20.7% 25.03 US$750,756
2017-01-20 2017-01-18 PlS Planned sale Litton Mark James

Chief Business Officer
1,498 -1.5%
23.10
US$34,599 		1,498 -1.5% 23.10 US$34,599
2017-01-09 2017-01-09 PlS Planned sale Litton Mark James

Chief Business Officer
500 -0.5%
23.00
US$11,500 		500 -0.5% 23.00 US$11,500
2017-01-09 2017-01-06 PlS Planned sale Litton Mark James

Chief Business Officer
6,800 -6.4%
23.02
US$156,520 		6,800 -6.4% 23.02 US$156,520
2017-01-09 2017-01-05 PlS Planned sale Litton Mark James

Chief Business Officer
2,216 -2.2%
23.00
US$50,972 		2,216 -2.2% 23.00 US$50,972
2016-12-05 2016-12-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
500 -0.2%
23.62
US$11,810 		500 -0.2% 23.62 US$11,810
2016-12-05 2016-12-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
3,136 -1.3%
22.64
US$71,002 		3,136 -1.3% 22.64 US$71,002
2016-12-05 2016-12-01 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
500 -37.6%
23.62
US$11,810 		500 -37.6% 23.62 US$11,810
2016-12-05 2016-12-01 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
2,500 -65.3%
22.61
US$56,518 		2,500 -65.3% 22.61 US$56,518
2016-11-14 2016-11-09 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
10,000 -4.0%
30.18
US$301,839 		10,000 -4.0% 30.18 US$301,839
2016-11-09 2016-11-07 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
10,000 -8.0%
25.16
US$251,605 		10,000 -8.0% 25.16 US$251,605
2016-11-03 2016-11-01 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
400 -100.0%
24.88
US$9,950 		400 -100.0% 24.88 US$9,950
2016-11-03 2016-11-01 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
2,600 -86.7%
24.26
US$63,082 		2,600 -86.7% 24.26 US$63,082
2016-10-19 2016-10-17 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
2,000 -7.1%
27.50
US$55,000 		2,000 -7.1% 27.50 US$55,000
2016-10-19 2016-10-17 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
2,000 -7.1%
27.50
US$55,005 		2,000 -7.1% 27.50 US$55,005
2016-10-19 2016-10-17 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
2,000 -7.1%
27.50
US$54,993 		2,000 -7.1% 27.50 US$54,993
2016-10-05 2016-10-03 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
6,249 -2.5%
31.51
US$196,888 		6,249 -2.5% 31.51 US$196,888
2016-10-05 2016-10-03 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
3,751 -1.5%
31.00
US$116,263 		3,751 -1.5% 31.00 US$116,263
2016-10-05 2016-10-03 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
702 -100.0%
31.62
US$22,199 		702 -100.0% 31.62 US$22,199
2016-10-05 2016-10-03 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
2,298 -76.6%
30.99
US$71,216 		2,298 -76.6% 30.99 US$71,216
2016-10-05 2016-10-03 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
2,700 -2.3%
31.55
US$85,189 		2,700 -2.3% 31.55 US$85,189
2016-10-05 2016-10-03 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
5,481 -4.5%
30.95
US$169,622 		5,481 -4.5% 30.95 US$169,622
2016-09-06 2016-09-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
10,000 -4.0%
32.49
US$324,949 		10,000 -4.0% 32.49 US$324,949
2016-09-06 2016-09-01 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
10,000 -8.0%
32.48
US$324,820 		10,000 -8.0% 32.48 US$324,820
2016-09-06 2016-09-01 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
100 -100.0%
33.10
US$3,310 		100 -100.0% 33.10 US$3,310
2016-09-06 2016-09-01 PlS Planned sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
2,900 -96.7%
32.47
US$94,173 		2,900 -96.7% 32.47 US$94,173
2016-08-17 2016-08-15 S Sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
3,000 -100.0%
31.17
US$93,512 		3,000 -100.0% 31.17 US$93,512
2016-08-03 2016-08-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
32 -0.0%
32.54
US$1,041 		32 -0.0% 32.54 US$1,041
2016-08-03 2016-08-01 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
6,394 -2.5%
30.88
US$197,423 		6,394 -2.5% 30.88 US$197,423
2016-08-03 2016-08-01 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
16 -0.0%
32.69
US$523 		16 -0.0% 32.69 US$523
2016-08-03 2016-08-01 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
4,816 -4.0%
31.68
US$152,570 		4,816 -4.0% 31.68 US$152,570
2016-08-03 2016-08-01 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
5,168 -4.1%
30.65
US$158,420 		5,168 -4.1% 30.65 US$158,420
2016-07-28 2016-07-27 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
9,187 -3.7%
30.15
US$277,023 		9,187 -3.7% 30.15 US$277,023
2016-07-28 2016-07-26 PlS Planned sale Latham John A

Chief Scientific Officer

Officer
813 -0.3%
30.00
US$24,392 		813 -0.3% 30.00 US$24,392
2016-07-27 2016-07-25 PlS Planned sale Schatzman Randall C

President and CEO

Executive Director
10,000 -8.0%
28.08
US$280,805 		10,000 -8.0% 28.08 US$280,805
2016-06-15 2016-06-13 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
200 -0.7%
29.64
US$5,928 		200 -0.7% 29.64 US$5,928
2016-06-15 2016-06-13 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
1,800 -6.0%
28.90
US$52,012 		1,800 -6.0% 28.90 US$52,012
2016-06-15 2016-06-13 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
100 -0.4%
29.60
US$2,960 		100 -0.4% 29.60 US$2,960
2016-06-15 2016-06-13 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
1,900 -6.3%
28.89
US$54,900 		1,900 -6.3% 28.89 US$54,900
2016-06-15 2016-06-13 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
100 -0.4%
29.60
US$2,960 		100 -0.4% 29.60 US$2,960
2016-06-15 2016-06-13 PlS Planned sale Litton Mark James

Chief Business Officer

Officer
1,900 -6.3%
28.90
US$54,903 		1,900 -6.3% 28.90 US$54,903
2016-06-07 2016-06-03 S Sale Smith Jeffrey T L

Sr. VP Translational Medicine

Officer
1,000 -100.0%
31.83
US$31,827 		1,000 -100.0% 31.83 US$31,827
Explore more

More insider trading research around Alder Biopharmaceuticals Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America